Previous 10 | Next 10 |
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
WALTHAM, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the appointment of Carrie Melvin as Chief Operating O...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“ Celularity ”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board o...
Foghorn has partnering deals with major big pharma. They have a novel technology which no one else seems to have. If they can do proof of concept, they may go up considerably. For further details see: Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportun...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
The following slide deck was published by Kura Oncology, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Kura Oncology, Inc. 2022 Q1 - Results - Earnings Call Presentation
Kura Oncology, Inc. (KURA) Q1 2022 Earnings Conference Call May 4, 2022, 4:30 PM ET Company Participants Troy Wilson – Chairman and Chief Executive Officer Tom Doyle – Senior Vice President, Finance and Accounting Pete De Spain – Senior Vice President, Investor Relations ...
Kura Oncology press release (NASDAQ:KURA): Q1 GAAP EPS of -$0.49 beats by $0.03. Cash, cash equivalents and short-term investments totaled $480.1M as of Mar. 31, 2022, compared with $518M as of Dec. 31, 2021. "We continue to operate from a position of strength, armed with three independent dr...
– Enrollment completed in Phase 1b expansion cohorts for ziftomenib; topline data expected in third quarter, full data presentation in fourth quarter – – Enrollment in PIK3CA-dependent cohort in KURRENT-HN trial of tipifarnib plus alpelisib continues; first patien...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 22:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 08:15:04 ET H.C. Wainwright analyst issues BUY recommendation for KURA on June 25, 2024 06:44AM ET. The previous analyst recommendation was Buy. KURA was trading at $21.08 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
– Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes – – Kura advancing multiple, next-generation menin inhibitor drug candidates targeting diabetes and other metabolic diseases ...